Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enhabit, Inc. (NYSE: EHAB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a public issuer. Enhabit, which operates as Enhabit Home Health & Hospice, files reports with the U.S. Securities and Exchange Commission that describe its home health and hospice business, financial performance, governance matters, and executive compensation arrangements.
Through its Form 8-K filings, Enhabit reports material events such as quarterly earnings releases, participation in investor conferences, leadership changes, and stockholder meeting results. For example, the company has filed 8-Ks to furnish its earnings press releases and supplemental information for quarters ended March 31, June 30, and September 30, as well as to describe a CEO transition plan, retention awards for senior officers, and approval of the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan at its annual meeting.
Enhabit’s filings also identify its common stock as registered under Section 12(b) of the Exchange Act and traded on the New York Stock Exchange under the symbol EHAB. The company uses its SEC reports to explain its use of non-GAAP measures such as Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted EPS, and Adjusted free cash flow, and to discuss how unusual or nonrecurring items affect the reconciliation to GAAP results. Same-store comparison methodology for home health and hospice locations is also described in these materials.
On this page, users can review Enhabit’s SEC filings in chronological order, including 8-Ks that detail results of operations and financial condition, regulation FD disclosures, equity plan approvals, and stockholder voting outcomes. Stock Titan’s tools surface these documents alongside AI-powered summaries that highlight key points, helping readers quickly understand how each filing relates to Enhabit’s home health and hospice operations, capital structure, and governance.
Investors and researchers can use this filings archive to follow Enhabit’s reported net service revenue trends, segment performance, executive and director arrangements, and the regulatory context around its home-based care business, all sourced from the company’s official submissions to the SEC’s EDGAR system.
Enhabit, Inc. Chief Human Resources Officer Marion Tanya Renee reported equity compensation activity and related tax withholding in company stock. On February 27, 2026, she acquired 14,425 shares of common stock at $13.58 per share through a grant or award.
That same day, 5,928 shares were withheld at $13.58 per share to cover tax obligations tied to vesting of performance-based restricted stock units for the 2023–2025 period. On March 1, 2026, additional tax-withholding dispositions of 1,040 shares and 1,976 shares occurred at $13.61 per share. Following these transactions, she directly held 89,291 shares of common stock, with a further 1,712 shares held indirectly by her spouse.
Enhabit, Inc. executive Julie Diane Jolley reported equity compensation activity in the form of restricted stock vesting and related tax withholding. On February 27, 2026, she acquired 21,430 shares of common stock from performance-based restricted stock units, while several smaller blocks of shares were withheld at prices around $13.58–$13.61 per share to satisfy tax obligations.
Enhabit, Inc. President and CEO Barbara Ann Jacobsmeyer reported several equity compensation transactions involving the company’s common stock. On February 27, 2026, she acquired 117,671 shares through the vesting of performance-based restricted stock units covering the 2023–2025 period. On the same date and on March 1, 2026, she disposed of multiple blocks of shares (including 46,504, 4,591 and 14,993 shares) as tax-withholding dispositions, where shares were withheld or surrendered to cover tax obligations related to the vesting rather than sold in open-market trades. Following these transactions, she continued to hold a substantial direct ownership position in Enhabit common stock as reflected in the reported post-transaction share balances.
Enhabit, Inc. executive Jeanne Louise Kalvaitis, EVP of Hospice Operations, reported equity award activity and related tax withholding transactions in common stock. On February 27, 2026, she acquired 9,824 shares through a grant/award at $13.58 per share, tied to performance-based restricted stock units.
On February 27 and March 1, 2026, a total of 4,055 shares were disposed of at per‑share prices of $13.58 and $13.61 to satisfy tax withholding obligations on vested restricted stock, rather than through open‑market sales. After these transactions, she directly held 51,748 common shares.
Enhabit, Inc. reported that Senior Vice President and Chief Accounting Officer Collin McQuiddy has decided to resign, effective March 27, 2026. He will remain with the company until that date to help transition his responsibilities and is leaving to pursue another career opportunity.
The company stated there were no disagreements with Mr. McQuiddy regarding operations, policies, or practices. After the transition date, Chief Financial Officer Ryan Solomon will also serve as principal accounting officer until a successor is appointed, without any change or increase in his compensation.
Enhabit, Inc. agreed to be acquired by affiliates of Kinderhook Industries in an all‑cash merger at $13.80 per share. Each outstanding Enhabit common share (with limited exceptions) will be converted into the right to receive this cash amount at closing.
The deal implies a total enterprise value of about $1.1 billion and represents a 24.4% premium to Enhabit’s February 20, 2026 closing price and a 33.8% premium to its 60‑day volume‑weighted average price. After the merger, Enhabit will become a private company and its stock will be delisted from the New York Stock Exchange.
Equity awards will generally vest at the merger time and be cashed out at the $13.80 price, with out‑of‑the‑money options cancelled. Closing requires majority stockholder approval, antitrust and other regulatory clearances, and absence of a Company Material Adverse Effect, and is targeted for the second quarter of 2026.
8 Knots Management and affiliated funds report a significant passive stake in Enhabit, Inc. common stock. As of January 31, 2026, they beneficially own 5,057,352 shares, representing 9.99% of Enhabit’s 50,607,075 outstanding shares. The position is held through the 8 Knots Fund complex, a sub-advised fund, and several separately managed accounts, with varying levels of investment discretion and beneficial ownership. The filers certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Enhabit.
Enhabit, Inc. filed a Form 8-K to share an update on a Delaware fiduciary duty case. Enhabit and Encompass Health Corporation have collected $43.1 million in full satisfaction of their claims for attorneys’ fees and mitigation damages from three individual defendants.
The companies will split the $43.1 million substantially equally. They also remain entitled, under a prior Court of Chancery order, to share 43% of VitalCaring Group’s ongoing profits and exit proceeds if and when VitalCaring is sold, through a constructive trust that is unchanged for the non-settling defendants.
Enhabit, Inc. director Barry P. Schochet reported receiving 2,382 shares of common stock on January 10, 2026. The shares were awarded at $9.97 per share and are structured as deferred stock units.
These units were taken in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan. Following this transaction, Schochet beneficially owns 70,232 shares of Enhabit common stock in direct ownership.
Enhabit, Inc. director Stephan Rodgers reported receiving 1,881 shares of common stock on January 10, 2026 at a price of $9.97 per share. This was reported as an acquisition and increased his directly held position to 19,998 shares of Enhabit common stock.
According to the footnote, these 1,881 shares are deferred stock units granted in lieu of a cash retainer fee, based on his election under the Enhabit, Inc. Deferred Director Compensation Plan. This filing reflects routine director compensation paid in equity rather than cash.